Pancreatic Cancer Research

ResearcherPhilipps University of MarburgNo recent work listed

Volker Fendrich

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4454-1901; OpenAlex author ID A5103221756, A5103607718. Sources: OpenAlex.

Their work

Papers
22 (first author 4, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
53
Papers, trials and grants by year

2011: 4 papers · 2012: 1 paper · 2013: 4 papers · 2014: 4 papers · 2015: none · 2016: 3 papers · 2017: none · 2018: 4 papers · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper

Papers 22

  1. Effects of Monoamino-Oxidase-A (MAO-A) Inhibition on Skeletal Muscle Inflammation and Wasting through Pancreatic Ductal Adenocarcinoma in Triple Transgenic Mic… Co-author DOI 10.3390/biomedicines11030912↗
  2. Inflammation and Wasting of Skeletal Muscles in Kras-p53-Mutant Mice with Intraepithelial Neoplasia and Pancreatic Cancer-When Does Cachexia Start? Co-author DOI 10.3390/cells11101607↗
  3. Expression of neuropeptide Y and its receptors Y1 and Y2 in pancreatic intraepithelial neoplasia and invasive pancreatic cancer in a transgenic mouse model and… First author DOI 10.1016/j.jss.2017.11.010↗
  4. Genetic and pharmacologic abrogation of Snail1 inhibits acinar-to-ductal metaplasia in precursor lesions of pancreatic ductal adenocarcinoma and pancreatic inj… Co-author DOI 10.1038/s41388-017-0100-4↗
  5. Chemoprevention and Treatment of Pancreatic Cancer: Update and Review of the Literature. First author DOI 10.1159/000485741↗
  6. Familial Pancreatic Cancer. First author DOI 10.1159/000493473↗
  7. Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells. Co-author DOI 10.1038/onc.2015.270↗
  8. Refinement of screening for familial pancreatic cancer. Co-author DOI 10.1136/gutjnl-2015-311098↗
  9. Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers. Co-author DOI 10.1200/jco.2015.64.0730↗
  10. Familial pancreatic cancer--status quo. Co-author DOI 10.1007/s00384-013-1760-3↗
  11. Chronic pancreatitis and systemic inflammatory response syndrome prevent impact of chemotherapy with gemcitabine in a genetically engineered mouse model of pan… Last author DOI 10.1016/j.neo.2014.05.010↗
  12. MicroRNA-196a and -196b as Potential Biomarkers for the Early Detection of Familial Pancreatic Cancer. Co-author DOI 10.1016/j.tranon.2014.05.007↗
  13. The role of pancreatic and duodenal homeobox 1 as a therapeutic target in pancreatic cancer. Co-author DOI 10.1517/14728222.2014.945427↗
  14. Aspirin prolongs survival and reduces the number of Foxp3+ regulatory T cells in a genetically engineered mouse model of pancreatic cancer. Last author DOI 10.1007/s00423-013-1105-2↗
  15. Simvastatin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer. Co-author DOI 10.1016/j.pan.2013.08.002↗
  16. Claudin-4-targeted optical imaging detects pancreatic cancer and its precursor lesions. Co-author DOI 10.1136/gutjnl-2012-302577↗
  17. LCN2 and TIMP1 as Potential Serum Markers for the Early Detection of Familial Pancreatic Cancer. First author DOI 10.1593/tlo.12373↗
  18. Chemoprevention of pancreatic cancer-one step closer. Co-author DOI 10.1007/s00423-012-0916-x↗
  19. German national case collection for familial pancreatic cancer (FaPaCa): ten years experience. Co-author DOI 10.1007/s10689-010-9414-x↗
  20. Detection of precursor lesions of pancreatic adenocarcinoma in PET-CT in a genetically engineered mouse model of pancreatic cancer. Co-author DOI 10.1593/neo.10956↗
  21. Inactivation of Brca2 cooperates with Trp53(R172H) to induce invasive pancreatic ductal adenocarcinomas in mice: a mouse model of familial pancreatic cancer. Last author DOI 10.4161/cbt.11.11.15534↗
  22. Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Co-author DOI 10.4161/cbt.12.7.16475↗

Closest collaborators

The 25 strongest of 53 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Detlef Klaus Bartsch · 13 shared papers, 2011–2018 · strength 0.60
  2. Emily P. Slater · 8 shared papers, 2011–2023 · strength 0.57
  3. Julia Benzel · 2 shared papers, 2018 · strength 0.34
  4. Simon K. P. Schmich · 2 shared papers, 2022–2023 · strength 0.32
  5. Wulf Hildebrandt · 2 shared papers, 2022–2023 · strength 0.32
  6. Ralf Kinscherf · 2 shared papers, 2022–2023 · strength 0.32
  7. Jens Waldmann · 5 shared papers, 2013–2018 · strength 0.29
  8. Peter Langer · 6 shared papers, 2011–2016 · strength 0.26
  9. Matthias Lauth · 4 shared papers, 2013–2018 · strength 0.25
  10. Julia P. N. Holler · 2 shared papers, 2018 · strength 0.16
  11. Günter Klöppel · 3 shared papers, 2014–2016 · strength 0.12
  12. Lars Plaßmeier · 3 shared papers, 2013–2014 · strength 0.12
  13. Richard Friedemann Knoop · 3 shared papers, 2013–2014 · strength 0.12
  14. Thomas Mathias Gress · 3 shared papers, 2013–2016 · strength 0.11
  15. Isaura S. Ibrahim · 2 shared papers, 2016 · strength 0.08
  16. Evelina Mocci · 2 shared papers, 2016 · strength 0.08
  17. Enrique Vázquez-Sequeiros · 2 shared papers, 2016 · strength 0.08
  18. Bert A. Bonsing · 2 shared papers, 2016 · strength 0.08
  19. Alfredo Carrato Mena · 2 shared papers, 2016 · strength 0.08
  20. Carmen Guillén‐Ponce · 2 shared papers, 2016 · strength 0.08
  21. Hans F. A. Vasen · 2 shared papers, 2016 · strength 0.08
  22. Julie Earl · 2 shared papers, 2016 · strength 0.08
  23. Martin N.J.M. Wasser · 2 shared papers, 2016 · strength 0.08
  24. Iréne Esposito · 2 shared papers, 2014–2016 · strength 0.08
  25. Anirban Maitra · 3 shared papers, 2011 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.